TABLE 4.
In vitro activity of the new fluoroquinolones and ciprofloxacin against other clinically important bacteria
| Bacteria | Fluoroquinolones | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ciprofloxacin | Clinafloxacin | Gatifloxacin | Grepafloxacin | Levofloxacin | Moxifloxacin | Sparfloxacin | Trovafloxacin | |||||||||
| MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | |
| Chlamydia pneumoniae | 1 | 2 | NA | NA | 0.063 | 0.13 | NA | 0.12 | 0.25 | 0.5 | 1 | 1 | 0.063 | 0.063 | 1 | 1 |
| Legionella pneumophila | 0.03 | 0.06 | 0.008 | 0.015 | NA | NA | 0.015 | 0.015 | 0.016 | 0.032 | 0.015 | 0.015 | 0.004 | 0.004 | 0.004 | 0.004 |
| Mycoplasma pneumoniae | 1 | 2 | 0.016 | 0.031 | NA | 0.06 | NA | 0.5 | 0.25 | 0.5 | 0.06 | 0.12 | 0.13 | 0.13 | 0.25 | 0.25 |
| Ureaplasma urealyticum | 4 | 4 | 0.13 | 0.25 | 0.25 | 0.5 | NA | 0.5 | 0.5 | 1 | 0.12 | 0.12 | 0.25 | 0.5 | 0.13 | 0.5 |
MIC50 Minimum inhibitory concentration of 50% of isolates; MIC90 MIC of 90% of isolates; NA Information not available. Adapted from references: ciprofloxacin 96–99; clinafloxacin 98,99; gatifloxacin 97,99; grepafloxacin 101; levofloxacin 97,99,102,103; moxifloxacin 70,104,105; sparfloxacin 96–98; trovafloxacin 96,106,107